Clinical review report Tocilizumab (Actemra) (Hoffmann-La Roche Limited)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults.
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820281406719 |
| Sumario: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults. |
|---|---|
| Descripción Física: | 1 online resource (1 PDF file (63 pages)) : illustrations |
